BVF Inc’s Enanta Pharmaceuticals ENTA Stock Holding History

BVF Inc’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-153,500	Closed	-$2.72M	–	28
2013 Q2	$2.72M	Buy	+153,500	New	+$2.99M	0.53%	19

Other funds holding ENTA

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

AlpInvest Partners Amsterdam, Netherlands $49.7M AUM 23.93% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

WSA

Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Bailard Foster City, California $4.91B AUM 31.75% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

SONJCPFA

State of New Jersey Common Pension Fund A Trenton, New Jersey $223M AUM 26.5% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BVF Inc's ENTA Position: Q3 2013 in Review

BVF Inc sold out of Enanta Pharmaceuticals (ENTA) in Q3 2013, closing a stake of 153,500 shares — an estimated $2.72M sold.

BVF Inc first reported a position in ENTA in Q2 2013 and held it in 1 quarter. The position peaked at $2.72M in Q2 2013. 54 funds tracked by Wall St. Rank hold ENTA as of Q3 2013.

BVF Inc reported no remaining Enanta Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
BVF Inc sold 153,500 Enanta Pharmaceuticals shares in Q3 2013, an estimated $2.72M.
BVF Inc first reported a position in Enanta Pharmaceuticals in Q2 2013 and held it in 1 quarter.
BVF Inc's Enanta Pharmaceuticals position peaked at $2.72M in Q2 2013.
54 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2013.

Based on BVF Inc's 13F filing for Q3 2013, filed 14 Nov 2013.